Cell and gene therapeutics is a rapidly developing industry, delivering promising treatments and even cures for many of the world’s worst diseases. Personalized medicine and immunotherapy companies are at the forefront, producing breakthroughs faster than ever before, even for rare diseases.
But, when it comes time to manufacture these cutting-edge products, 80% of batch records are still paper based! This can slow things way down. However, implementing a legacy manufacturing execution system (MES) is often too expensive and time consuming. Cell and gene therapy companies need a digital, paperless manufacturing solution that is affordable and can be implemented quickly, while also being nimble and scalable to support smaller batch sizes. Pioneers in the industry are digitizing with next gen MES software, that is cloud-based and designed to meet their evolving needs.
Brian Curran, senior vice president of manufacturing excellence at MasterControl, offers a glimpse into where the cell and gene therapy manufacturing industry sits, how it’s evolving, and how modern, cloud-based MES solutions are helping cell and gene therapy pioneers deliver right-first-time products to patients faster.
Learn more about our Modern MES at [ Ссылка ]
Subscribe for more informative content [ Ссылка ]
0:00 Introduction
3:52 Legacy Manufacturing execution systems (MES)
5:29 Cell and Gene Therapeutics Needs
8:33 Common Problems for Cell and Gene Therapeutics
16:11 Technology Benefits for Cell and Gene Therapeutics
21:55 Business Value Example
26:00 Q&A
